Experts have discovered that kidney transplant patients who take statins could reduce their heart attack risk by a third. A total of 1788 kidney transplant patients completed an international study led by researchers at the National Hospital in Oslo, Norway. Approximately half of the participants were given fluvastatin, and the other half were given a placebo. After 5 years, there were 70 heart attacks in the statin group, compared with 104 in the control group. The researchers found that the risk of a fatal heart attack was 38% lower among the statin group, compared with those taking the placebo, whereas the risk of a nonlethal heart attack was 32% lower in those taking the statin. The findings were recently published on the Web site of The Lancet.
Kidney transplant patients are more at risk for premature cardiovascular disease; many of them already have heart disease at the time of their transplants. Also, immune-system?suppressing drugs may aggravate existing heart disease risk factors such as high cholesterol.
"This new multicenter study shows yet another group that will benefit from statins," said Sir Charles George, medical director for the British Heart Foundation, which was not connected with the study. "This study shows that some kidney patients can . . . benefit from a statin and reduce their coronary heart disease, without dangerous side effects."
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs